Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Platelet activation and neutrophil extracellular trap (NET) formation in immune thrombocytopenia: is there an association?

Lozano ML, Garabet L, Fernandez-Perez MP, De Los Reyes-García AM, Diaz-Lozano P, Garcia-Barbera N, Aguila S, Vicente V, Ghanima W, Martinez C, Gonzalez-Conejero R.

Platelets. 2019 Nov 24:1-7. doi: 10.1080/09537104.2019.1696456. [Epub ahead of print]

PMID:
31762368
2.

In Silico Design of Novel Mutant Anti-MUC1 Aptamers for Targeted Cancer Therapy.

Santini BL, Zúñiga-Bustos M, Vidal-Limon A, Alderete JB, Águila SA, Jiménez VA.

J Chem Inf Model. 2019 Nov 4. doi: 10.1021/acs.jcim.9b00756. [Epub ahead of print]

PMID:
31657548
3.

TNF-α-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging.

Davizon-Castillo P, McMahon B, Aguila S, Bark D, Ashworth K, Allawzi A, Campbell RA, Montenont E, Nemkov T, D'Alessandro A, Clendenen N, Shih L, Sanders NA, Higa K, Cox A, Padilla-Romo Z, Hernandez G, Wartchow E, Trahan GD, Nozik-Grayck E, Jones K, Pietras EM, DeGregori J, Rondina MT, Di Paola J.

Blood. 2019 Aug 29;134(9):727-740. doi: 10.1182/blood.2019000200. Epub 2019 Jul 16.

4.

Molecular modeling simulation studies reveal new potential inhibitors against HPV E6 protein.

Ricci-López J, Vidal-Limon A, Zunñiga M, Jimènez VA, Alderete JB, Brizuela CA, Aguila S.

PLoS One. 2019 Mar 15;14(3):e0213028. doi: 10.1371/journal.pone.0213028. eCollection 2019.

5.

Increased galactose expression and enhanced clearance in patients with low von Willebrand factor.

Aguila S, Lavin M, Dalton N, Patmore S, Chion A, Trahan GD, Jones KL, Keenan C, Brophy TM, O'Connell NM, Ryan K, Byrne M, Nolan M, Patel A, Preston RJS, James P, Di Paola J, O'Sullivan JM, O'Donnell JS.

Blood. 2019 Apr 4;133(14):1585-1596. doi: 10.1182/blood-2018-09-874636. Epub 2019 Feb 15.

PMID:
30770394
6.

Novel therapies for hemophilia A - the role of the von Willebrand factor chaperone.

Aguila S, O'Donnell JS.

J Thromb Haemost. 2019 Mar;17(3):426-428. doi: 10.1111/jth.14353. Epub 2019 Jan 16. No abstract available.

PMID:
30652400
7.

Bismuth germanate (Bi4Ge3O12), a promising high-capacity lithium-ion battery anode.

Rodriguez JR, Belman-Rodriguez C, Aguila SA, Zhang Y, Liu H, Pol VG.

Chem Commun (Camb). 2018 Oct 9;54(81):11483-11486. doi: 10.1039/c8cc05861j.

PMID:
30256349
8.

Significant gynecological bleeding in women with low von Willebrand factor levels.

Lavin M, Aguila S, Dalton N, Nolan M, Byrne M, Ryan K, White B, O'Connell NM, O'Sullivan JM, Di Paola J, James PD, O'Donnell JS.

Blood Adv. 2018 Jul 24;2(14):1784-1791. doi: 10.1182/bloodadvances.2018017418.

9.

Scoring of Side-Chain Packings: An Analysis of Weight Factors and Molecular Dynamics Structures.

Colbes J, Aguila SA, Brizuela CA.

J Chem Inf Model. 2018 Feb 26;58(2):443-452. doi: 10.1021/acs.jcim.7b00679. Epub 2018 Feb 9.

PMID:
29368924
10.

Enhanced Degradation of Pesticide Dichlorophen by Laccase Immobilized on Nanoporous Materials: A Cytotoxic and Molecular Simulation Investigation.

Vidal-Limon A, García Suárez PC, Arellano-García E, Contreras OE, Aguila SA.

Bioconjug Chem. 2018 Apr 18;29(4):1073-1080. doi: 10.1021/acs.bioconjchem.7b00739. Epub 2018 Mar 7.

PMID:
29337540
11.

A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance.

Ward SE, O'Sullivan JM, Drakeford C, Aguila S, Jondle CN, Sharma J, Fallon PG, Brophy TM, Preston RJS, Smyth P, Sheils O, Chion A, O'Donnell JS.

Blood. 2018 Feb 22;131(8):911-916. doi: 10.1182/blood-2017-06-787853. Epub 2017 Dec 27.

PMID:
29282218
12.

Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Lavin M, Aguila S, Schneppenheim S, Dalton N, Jones KL, O'Sullivan JM, O'Connell NM, Ryan K, White B, Byrne M, Rafferty M, Doyle MM, Nolan M, Preston RJS, Budde U, James P, Di Paola J, O'Donnell JS.

Blood. 2017 Nov 23;130(21):2344-2353. doi: 10.1182/blood-2017-05-786699. Epub 2017 Sep 15.

13.

Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities.

Águila S, Izaguirre G, Martínez-Martínez I, Vicente V, Olson ST, Corral J.

J Biol Chem. 2017 Oct 6;292(40):16513-16520. doi: 10.1074/jbc.M117.787325. Epub 2017 Jul 25.

14.

A workflow for in silico design of hIL-10 and ebvIL-10 inhibitors using well-known miniprotein scaffolds.

Dueñas S, Aguila SA, Pimienta G.

J Mol Model. 2017 Apr;23(4):118. doi: 10.1007/s00894-017-3276-1. Epub 2017 Mar 14.

PMID:
28293795
15.

A biosensor based on Coriolopsis gallica laccase immobilized on nitrogen-doped multiwalled carbon nanotubes and graphene oxide for polyphenol detection.

Aguila SA, Shimomoto D, Ipinza F, Bedolla-Valdez ZI, Romo-Herrera J, Contreras OE, Farías MH, Alonso-Núñez G.

Sci Technol Adv Mater. 2015 Oct 16;16(5):055004. eCollection 2015 Oct.

16.

N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor.

O'Sullivan JM, Aguila S, McRae E, Ward SE, Rawley O, Fallon PG, Brophy TM, Preston RJ, Brady L, Sheils O, Chion A, O'Donnell JS.

J Thromb Haemost. 2016 Dec;14(12):2446-2457. doi: 10.1111/jth.13537. Epub 2016 Dec 9.

17.

N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance.

Chion A, O'Sullivan JM, Drakeford C, Bergsson G, Dalton N, Aguila S, Ward S, Fallon PG, Brophy TM, Preston RJ, Brady L, Sheils O, Laffan M, McKinnon TA, O'Donnell JS.

Blood. 2016 Oct 13;128(15):1959-1968. Epub 2016 Aug 23.

18.

Heparanase Activates Antithrombin through the Binding to Its Heparin Binding Site.

Bohdan N, Espín S, Águila S, Teruel-Montoya R, Vicente V, Corral J, Martínez-Martínez I.

PLoS One. 2016 Jun 20;11(6):e0157834. doi: 10.1371/journal.pone.0157834. eCollection 2016.

19.

Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase.

Luengo-Gil G, Calvo MI, Martín-Villar E, Águila S, Bohdan N, Antón AI, Espín S, Ayala de la Peña F, Vicente V, Corral J, Quintanilla M, Martínez-Martínez I.

Sci Rep. 2016 Jun 8;6:27544. doi: 10.1038/srep27544.

20.

Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency.

Navarro-Fernández J, de la Morena-Barrio ME, Padilla J, Miñano A, Bohdan N, Águila S, Martínez-Martínez I, Sevivas TS, de Cos C, Fernández-Mosteirín N, Llamas P, Asenjo S, Medina P, Souto JC, Overvad K, Kristensen SR, Corral J, Vicente V.

Thromb Haemost. 2016 Jul 4;116(1):146-54. doi: 10.1160/TH15-11-0871. Epub 2016 Apr 21.

PMID:
27098529

Supplemental Content

Loading ...
Support Center